obesity drug news today glp-1 2025 therapies are changing care. What does WHO recommend? Here's what you need to know Obesity GLP-1 Market
Description
In the SOUL trial, oral semaglutide showed a 14% MACE reduction (HR 0.86, 95% CI 0.770.96) [22]
This is Hims & Hers
How Effective Is It
26 Insulin Secretion Assay According to the experimental design, five islets of uniform size from each group were pre-incubated in Krebs Ringer Bicarbonate-HEPES solution supplemented with 2.8 mM glucose for 30 min
Diabetes Care 41(9):19811990
Semaglutide is less effective at reducing body weight in T2D patients compared to patients without (5% weight loss, SUSTAIN-6 and 15% weight loss, STEP, respectively)
